CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
CVRx, Inc. (NASDAQ: CVRX) has announced the publication of new data in JACC: Heart Failure, showcasing the long-term quality of life benefits of Barostim for heart failure patients with reduced ejection fraction. The data, from the BeAT-HF trial, demonstrates durable improvements up to 24 months in Minnesota Living with Heart Failure (MLWHF) and EuroQual-5D (EQ-5D) quality of life measures.
Patients receiving Barostim plus guideline-directed medical therapy (GDMT) reported significant improvements in physical and psychosocial measures compared to those receiving GDMT alone. These improvements included better ability to work around the house, sleep, and engage in activities with friends and family, as well as reduced depression and feelings of being a burden. Physically, patients reported less shortness of breath, fatigue, and pain, with increased mobility and ability to perform usual activities.
CVRx, Inc. (NASDAQ: CVRX) ha annunciato la pubblicazione di nuovi dati su JACC: Heart Failure, che evidenziano i benefici a lungo termine per la qualità della vita del Barostim per i pazienti con insufficienza cardiaca e frazione di eiezione ridotta. I dati, provenienti dal trial BeAT-HF, dimostrano miglioramenti durevoli fino a 24 mesi nelle misure di qualità della vita Minnesota Living with Heart Failure (MLWHF) e EuroQual-5D (EQ-5D).
I pazienti che hanno ricevuto Barostim insieme alla terapia medica lineare (GDMT) hanno riportato miglioramenti significativi nelle misure fisiche e psicosociali rispetto a quelli che hanno ricevuto solo GDMT. Questi miglioramenti includevano una migliore capacità di svolgere lavori domestici, di dormire e di partecipare ad attività con amici e familiari, oltre a una riduzione della depressione e del senso di essere un peso. Fisicamente, i pazienti hanno riferito minore mancanza di respiro, fatica e dolore, con un aumento della mobilità e della capacità di eseguire le normali attività.
CVRx, Inc. (NASDAQ: CVRX) ha anunciado la publicación de nuevos datos en JACC: Heart Failure, que muestran los beneficios a largo plazo en la calidad de vida del Barostim para pacientes con insuficiencia cardíaca y fracción de eyección reducida. Los datos, provenientes del ensayo BeAT-HF, demuestran mejoras duraderas de hasta 24 meses en las medidas de calidad de vida de Minnesota Living with Heart Failure (MLWHF) y EuroQual-5D (EQ-5D).
Los pacientes que recibieron Barostim junto con la terapia médica guiada por directrices (GDMT) informaron mejoras significativas en las medidas físicas y psicosociales en comparación con aquellos que solo recibieron GDMT. Estas mejoras incluyeron una mejor capacidad para realizar tareas en casa, dormir y participar en actividades con amigos y familiares, así como una reducción de la depresión y de la sensación de ser una carga. Físicamente, los pacientes informaron menos falta de aliento, fatiga y dolor, con un aumento en la movilidad y la capacidad para realizar actividades habituales.
CVRx, Inc. (NASDAQ: CVRX)는 JACC: Heart Failure에 새로운 데이터를 발표하며, 바로스팀이 심장 박출 분율이 낮은 심부전 환자들에게 장기적인 삶의 질 향상 보장을 제공한다는 내용을 보여주었습니다. 이 데이터는 BeAT-HF 시험에서 나온 것으로, 미네소타 심부전 생활 지수(MLWHF) 및 유로퀄-5D(EQ-5D) 삶의 질 지표에서 최대 24개월 동안의 지속적인 개선을 보여줍니다.
바로스팀과 가이드라인에 따른 의료요법(GDMT)을 함께 받은 환자들은 GDMT만 받은 환자들에 비해 유의미한 개선을 보고했습니다. 이러한 개선은 집안일을 하는 능력, 잠을 자는 능력, 친구 및 가족과 활동하는 능력의 향상뿐만 아니라 우울감 및 부담감을 줄이는 것을 포함합니다. 신체적으로, 환자들은 호흡 곤란, 피로감 및 통증이 줄어들었으며, 이동성과 일상 활동 수행 능력이 증가했습니다.
CVRx, Inc. (NASDAQ: CVRX) a annoncé la publication de nouvelles données dans JACC: Heart Failure, mettant en lumière les bénéfices à long terme pour la qualité de vie du Barostim pour les patients souffrant d'insuffisance cardiaque à fraction d'éjection réduite. Les données, issues de l'
Les patients ayant reçu Barostim en plus d'un traitement médical guidé par les recommandations (GDMT) ont rapporté des améliorations significatives dans les mesures physiques et psychosociales par rapport à ceux ayant seulement reçu la GDMT. Ces améliorations incluaient une meilleure capacité à effectuer des tâches ménagères, à dormir et à participer à des activités avec des amis et de la famille, ainsi qu'une réduction de la dépression et des sentiments de fardeau. Physiquement, les patients ont signalé moins d'essoufflement, de fatigue et de douleur, avec une augmentation de la mobilité et de la capacité à réaliser des activités habituelles.
CVRx, Inc. (NASDAQ: CVRX) hat die Veröffentlichung neuer Daten in JACC: Heart Failure angekündigt, die die langfristigen Vorteile für die Lebensqualität des Barostim für Herzinsuffizienzpatienten mit reduzierter Ejektionsfraktion präsentieren. Die Daten aus der BeAT-HF-Studie zeigen nachhaltige Verbesserungen von bis zu 24 Monaten in den Lebensqualitätsmaßen Minnesota Living with Heart Failure (MLWHF) und EuroQual-5D (EQ-5D).
Patienten, die Barostim zusammen mit leitliniengerechter medizinischer Therapie (GDMT) erhielten, berichteten von signifikanten Verbesserungen in physischen und psychosozialen Maßstäben im Vergleich zu denen, die nur GDMT erhielten. Zu diesen Verbesserungen gehörten eine bessere Fähigkeit, im Haushalt zu arbeiten, zu schlafen und sich an Aktivitäten mit Freunden und Familie zu beteiligen, sowie eine verringerte Depression und das Gefühl, eine Belastung zu sein. Körperlich berichteten die Patienten von weniger Atemnot, Müdigkeit und Schmerzen sowie von erhöhter Mobilität und der Fähigkeit, alltägliche Aktivitäten auszuführen.
- Publication of new data in JACC: Heart Failure reinforcing long-term benefits of Barostim
- Durable improvements in quality of life measures up to 24 months post-treatment
- Significant improvements in physical and psychosocial measures for patients receiving Barostim plus GDMT
- Reduced depression and feelings of being a burden reported by patients
- None.
Insights
This publication in JACC: Heart Failure provides compelling evidence for the long-term efficacy of Barostim in improving quality of life for heart failure patients. The 24-month data showing durable improvements in MLWHF and EQ-5D measures is particularly significant, as sustained benefits are often challenging to achieve in heart failure treatment.
The reported improvements in physical symptoms like reduced shortness of breath, fatigue and pain, coupled with enhanced mobility and ability to perform daily activities, suggest that Barostim could be a game-changer for patient care. Moreover, the psychological benefits, including reduced depression and feelings of being a burden, address a critical aspect of heart failure management often overlooked in traditional treatments.
From a research perspective, these results strengthen the case for Barostim as a complementary therapy to GDMT, potentially expanding treatment options for patients with reduced ejection fraction who struggle with persistent symptoms despite standard care.
The publication of this data in a prestigious journal like JACC: Heart Failure could have positive implications for CVRx's market position. Long-term efficacy data is important for medical devices and these results may strengthen CVRx's case for broader adoption of Barostim.
From a financial perspective, improved quality of life outcomes could drive increased demand for Barostim, potentially leading to higher sales and revenue growth for CVRx. The data might also support reimbursement discussions with payers, potentially improving the therapy's accessibility and market penetration.
However, investors should note that while this news is positive, the full financial impact may take time to materialize. It's important to monitor how quickly these results translate into increased physician adoption and patient demand. Additionally, keep an eye on CVRx's ability to scale production and sales operations to meet potential increased demand.
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart failure patients with reduced ejection fraction
MINNEAPOLIS, Sept. 12, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the publication of new data in the Journal of the American College of Cardiology: Heart Failure. The data detail the durable improvements out to 24-months in the individual components of the Minnesota Living with Heart Failure (MLWHF) and EuroQual-5D (EQ-5D) quality of life measures. The publication builds on the data from the BeAT-HF trial (NCT02627196) published in 2024 in the European Journal of Heart Failure demonstrating the long-term sustained symptomatic benefits of Barostim in heart failure patients with reduced ejection fraction.
“We know that many heart failure patients struggle with physical symptoms despite treatment with guideline-directed medical therapy (GDMT). As a result, patients’ reduced daily activity levels often adversely impact their emotional state and quality of life,” said Samuel F. Sears, PhD, Professor of Psychology at East Carolina University, and lead author of the publication. “While we know Barostim plus GDMT demonstrates long-term symptomatic benefits, we now have data demonstrating sustained improvement in specific symptoms and quality of life measures benefiting patients receiving the therapy.”
Patients in the trial with Barostim plus GDMT reported feeling significantly better in a variety of physical and psychosocial measures as compared to patients who received GDMT alone. This included significant improvement in their ability to work around the house, sleep, and engage in activities with friends and family. Patients receiving Barostim reported less depression and feeling they were less of a burden on friends and family. Physically, they reported less shortness of breath, less fatigue and pain, and increased mobility and ability to perform usual activities.
“Congratulations to Dr. Samuel Sears and colleagues for their detailed description of the ways Barostim alleviates the burden of heart failure and improves patients’ quality of life. The durable functional and psychological improvements associated with Barostim are unique to this therapy and superior to medical management alone. To see quality of life results that remain this significant in long-term data are rare,” said Dr. Philip Adamson, Chief Medical Officer of CVRx. “We believe this analysis of the long-term BeAT-HF data will support the shared decision making of patients and physicians when considering Barostim therapy.”
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Media Contact:
Laura O’Neill
Finn Partners
917.497.2867
laura.oneill@finnpartners.com
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443.213.0501
ir@cvrx.com
FAQ
What are the long-term benefits of Barostim for heart failure patients according to the new CVRx study?
How does Barostim compare to guideline-directed medical therapy (GDMT) alone for heart failure patients?
What specific quality of life improvements were observed in CVRx's Barostim study?
Where was the new CVRx Barostim data published and what trial did it come from?
